Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
PerkinElmer Inc. (PKI) drives innovation in diagnostics, life sciences, and applied markets through advanced scientific solutions. This page aggregates official announcements and verified news about the company's strategic initiatives, financial performance, and technological advancements.
Investors and industry professionals will find timely updates on earnings reports, product launches, and regulatory milestones. Our curated collection simplifies tracking PKI's progress in enabling critical research and improving healthcare outcomes globally.
Key content includes updates on analytical instrumentation developments, partnership announcements with research institutions, and expansions in diagnostic testing capabilities. All materials adhere to strict factual reporting standards without speculative commentary.
Bookmark this page for streamlined access to PerkinElmer's latest corporate communications. Check back regularly for insights into how PKI continues to address complex challenges in scientific discovery and clinical diagnostics.
Parkland Corporation (TSX: PKI) announced a dividend of $0.34 per share, to be paid on April 14, 2023, for shareholders of record by March 22, 2023. The ex-dividend date is set for March 21, 2023. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes, reflecting Parkland's commitment to returning value to its shareholders. The company's extensive operations span 25 countries, with approximately 4,000 retail locations across Canada, the U.S., and the Caribbean, highlighting its significant market presence and strategic growth initiatives.
PerkinElmer Inc. (NYSE: PKI) has completed the divestiture of its Applied, Food, and Enterprise Services businesses to New Mountain Capital. This strategic move allows PerkinElmer to focus on its new Life Sciences and Diagnostics company, which aims to drive scientific innovation and improve global health outcomes. The company plans to unveil a new name and ticker symbol in Q2 2023, pending shareholder approval. With approximately $3.3 billion in revenue in 2022 and operations in 190 countries, the restructured organization is poised for growth and will maintain strong commitments to service and corporate citizenship.
PerkinElmer (NYSE: PKI) announced its participation in the virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum scheduled for March 21, 2023, at 2:15 p.m. ET. Senior executives Steve Willoughby and Alan Fletcher will discuss the company's strategic priorities. Registration for the event is available here. A live audio webcast will be accessible on the company’s website, with a replay available for 30 days following the event.
PerkinElmer, a leader in the life sciences sector, has unveiled the EnVision® Nexus™ system, its most advanced multimode plate reader, at SLAS2023. This innovative platform enhances high-throughput screening (HTS) capabilities, significantly supporting drug discovery by allowing researchers to screen millions of samples with improved speed and accuracy. Additionally, PerkinElmer introduced the Zephyr® G3 NGS iQ™ workstation for automating NGS library preparation, further enhancing laboratory efficiency. With its robust portfolio and commitment to advancing scientific research, PerkinElmer aims to drive R&D productivity across various applications.
PerkinElmer (NYSE: PKI) will present at the Cowen 43rd Annual Health Care Conference on March 6 at 9:10 a.m. ET, with CFO Max Krakowiak, and the Barclays Global Healthcare Conference on March 14 at 8:00 a.m. ET, featuring CEO Prahlad Singh. The presentations will provide updates on the company's strategic priorities. Audio webcasts will be available on their website and replays will be accessible for 30 days.
PerkinElmer reported Q4 2022 revenue of $741 million, down from $1,028 million year-over-year, resulting in a 28% decline. The GAAP EPS was $0.85, down from $1.45 a year ago. Full-year revenue also decreased, totaling $3,312 million, compared to $3,828 million in 2021. Operating income dropped significantly, with a GAAP operating profit margin of 22.4% compared to 32.9% the previous year. Despite a challenging year, the company anticipates a 2023 revenue forecast of $2.94 billion with adjusted EPS of $5.05.
The Board of Directors of PerkinElmer (NYSE: PKI) has declared a regular quarterly dividend of
Amphenol Corporation (NYSE: APH) has appointed Dr. Prahlad Singh to its board of directors, expanding the board to 10 members. Dr. Singh, who is currently the President and CEO of PerkinElmer (NYSE: PKI), boasts over 25 years of global leadership experience in the healthcare and technology sectors. His background includes senior roles in major companies such as GE Healthcare and Philips Healthcare. The board views his extensive expertise in technology and mergers as valuable for Amphenol's growth strategy.
PerkinElmer Inc. (NYSE: PKI) will release its fourth quarter and full year 2022 financial results on February 14, 2023, before market open. A conference call led by CEO Prahlad Singh and CFO Max Krakowiak will take place at 8:00 a.m. ET on the same day. The company has updated its guidance for Q4 2022, anticipating results that will meet or exceed earlier projections made on November 8, 2022. PerkinElmer is a leader in life sciences and diagnostics, reporting about $5 billion in revenue in 2021 and operating in 190 countries.
PerkinElmer, a leader in health innovation, will present at the J.P. Morgan Healthcare Conference on January 10, 2023, at 8:15 a.m. PT. CEO Prahlad Singh is set to discuss the company's strategic priorities. Interested parties can access a live audio webcast of the presentation via a designated page, with a replay available on PerkinElmer's Investor Relations website for 30 days post-event. The company reported revenues of approximately $5 billion in 2021 and serves customers in 190 countries.
FAQ
What is the market cap of PERKINELMER (PKI)?
